Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

P Hammel; R Berardi; E Van Cutsem; J Feliu; Richard Greil; HS Wasan; JP Metges; P Nygren; PJ Osterlund; V Parner; T Seufferlein; A Gupta; S Salesse; N Biswasbaldwin; A Ibrahim; H Youssoufian; I El-Hariry; M Hidalgo

doi:10.1200/JCO.2019.37.4_suppl.TPS471

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

P Hammel, R Berardi, E Van Cutsem, J Feliu, Richard Greil, HS Wasan, JP Metges, P Nygren, PJ Osterlund, V Parner, T Seufferlein, A Gupta, S Salesse, N Biswasbaldwin, A Ibrahim, H Youssoufian, I El-Hariry, M Hidalgo

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

3 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	37
Issue number	4
DOIs	https://doi.org/10.1200/JCO.2019.37.4_suppl.TPS471
Publication status	Published - 2019
Event	Gastrointestinal Cancers Symposium - San Francisco, CA Duration: 17 Jan 2019 → 19 Jan 2019

Access to Document

10.1200/JCO.2019.37.4_suppl.TPS471

Cite this

Hammel, P., Berardi, R., Van Cutsem, E., Feliu, J., Greil, R., Wasan, HS., Metges, JP., Nygren, P., Osterlund, PJ., Parner, V., Seufferlein, T., Gupta, A., Salesse, S., Biswasbaldwin, N., Ibrahim, A., Youssoufian, H., El-Hariry, I., & Hidalgo, M. (2019). Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). JOURNAL OF CLINICAL ONCOLOGY , 37(4). https://doi.org/10.1200/JCO.2019.37.4_suppl.TPS471

Hammel, P ; Berardi, R ; Van Cutsem, E et al. / Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). In: JOURNAL OF CLINICAL ONCOLOGY 2019 ; Vol. 37, No. 4.

@article{58b332128f844146aea7a5a666edb51f,

title = "Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).",

author = "P Hammel and R Berardi and {Van Cutsem}, E and J Feliu and Richard Greil and HS Wasan and JP Metges and P Nygren and PJ Osterlund and V Parner and T Seufferlein and A Gupta and S Salesse and N Biswasbaldwin and A Ibrahim and H Youssoufian and I El-Hariry and M Hidalgo",

year = "2019",

doi = "10.1200/JCO.2019.37.4_suppl.TPS471",

language = "English",

volume = "37",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "4",

note = "Gastrointestinal Cancers Symposium ; Conference date: 17-01-2019 Through 19-01-2019",

}

Hammel, P, Berardi, R, Van Cutsem, E, Feliu, J, Greil, R, Wasan, HS, Metges, JP, Nygren, P, Osterlund, PJ, Parner, V, Seufferlein, T, Gupta, A, Salesse, S, Biswasbaldwin, N, Ibrahim, A, Youssoufian, H, El-Hariry, I & Hidalgo, M 2019, 'Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).', JOURNAL OF CLINICAL ONCOLOGY , vol. 37, no. 4. https://doi.org/10.1200/JCO.2019.37.4_suppl.TPS471

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). / Hammel, P; Berardi, R; Van Cutsem, E et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 37, No. 4, 2019.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).

AU - Hammel, P

AU - Berardi, R

AU - Van Cutsem, E

AU - Feliu, J

AU - Greil, Richard

AU - Wasan, HS

AU - Metges, JP

AU - Nygren, P

AU - Osterlund, PJ

AU - Parner, V

AU - Seufferlein, T

AU - Gupta, A

AU - Salesse, S

AU - Biswasbaldwin, N

AU - Ibrahim, A

AU - Youssoufian, H

AU - El-Hariry, I

AU - Hidalgo, M

PY - 2019

Y1 - 2019

U2 - 10.1200/JCO.2019.37.4_suppl.TPS471

DO - 10.1200/JCO.2019.37.4_suppl.TPS471

M3 - Abstract (Journal)

SN - 0732-183X

VL - 37

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 4

T2 - Gastrointestinal Cancers Symposium

Y2 - 17 January 2019 through 19 January 2019

ER -

Hammel P, Berardi R, Van Cutsem E, Feliu J, Greil R, Wasan HS et al. Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). JOURNAL OF CLINICAL ONCOLOGY . 2019;37(4). doi: 10.1200/JCO.2019.37.4_suppl.TPS471